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Molecular markers of sulfadoxine-pyrimethamine (SP) resistance were monitored in pregnant women 
of mean age 28 ± 11years in Makurdi, Nigeria. A total of 82 Plasmodium falciparum malaria positive blood 
samples were obtained prior to commencement of intermitt nt preventive treatment with SP (IPTp-SP) during 
antenatal visits. Of the 82 samples, 71 were successfully genotyped at the dihydrofolate reductase (dhfr) loci 
51, 59, 108 and 164; and dihydropteroate synthase (dhps) loci 436, 437, and 540. The genotyping was 
accomplished by means of polymerase chain reaction, and restriction fragment length polymorphisms. Theaim 
was to determine the percentage frequencies of P. alciparum single nucleotide polymorphisms (SNPs) 
associated with resistance to SP in vivo. The results show that both the dhfr and dhps genes each produced 5 
different haplotypes with varying percentage frequenci s. All genotyped gene loci had SNPs except dhfr 164 
and dhps 540. Haplotype combination of dhfr/dhps alleles yielded 15 different genotypes of P. falciparum 
parasites. The combined frequencies of triple/quadrple mutant haplotypes associated with in vivo SP 
resistance was 35.21%, but was significantly lower than single/double mutant haplotypes not associated with 
SP resistance (χ2 = 6.21, df = 1, p = 0.01). These results suggest a possible rise in in vivo SP resistance during 
IPTP-SP. There is a need for continuous monitoring of SP efficacy, for effective intermittent preventive 
treatment with the drug in the area.  
© 2014 International Formulae Group. All rights reserved. 
 




The synergistic antifolate drug 
combination, sulfadoxine-pyrimethamine (SP) 
has   played a critical role in the prevention 
and control of malaria since the late 1980s. 
This role was immensely appreciated 
particularly when it became evidently clear 
that resistance to chloroquine was extensive 
(Warhust, 2001) and the latter drug could not 
be relied upon as a drug of choice for the 
treatment of malaria as it had been the case in 
the past (WHO, 2005). However, it was a 
matter of time before widespread resistance to 
SP appeared in many parts of the world 




(Sibley et al., 2001; White, 2004). To date, 
despite huge evidence of falciparum malaria 
resistance to SP, its relevance in the 
intermittent preventive treatment of malaria in 
pregnancy (IPTP) is justified by lack of a 
better alternative drug to serve the same 
purpose (Vallely et al., 2007; WHO, 2010; 
WHO, 2013). Apart from its recommended 
use in the IPTP, the drug has also been 
recommended in combination with artesunate 
for the treatment of malaria in areas like the 
West African sub region, where resistance to 
the drug is comparably lower to other regions 
like South East Asia, South America, or East 
Africa (WHO, 2010). Thus in areas where P. 
falciparum resistance to the drug appears to be 
less wide spread, the continuous molecular 
survey of single nucleotide polymorphisms 
(SNPs) associated with decreasing sensitivity 
of the malaria parasites to SP in vivo is very 
relevant (Molecular Module WWARN, 2011). 
This is necessary in order to assess the 
continued relevance of SP as an antimalarial 
drug in the area of interest, among the groups 
that rely on it.   
In Nigeria, SP is commonly available 
over the counter in both rural and urban areas 
at patent medicine stores (Okeke et al., 2006). 
Because of its cheaper cost compared to 
artemether/lumefantrine, SP is still being used 
by many people as a single dose therapy for 
self treatment of suspected cases of acute 
malaria infections (Omole and Onademuren, 
2010). This negates the main purpose for 
which the drug is currently recommended 
(WHO, 2013). The practice is particularly 
common among patent medicine vendors who 
often prescribe and vend various brands of SP 
available in their drug stores, for the treatment 
of any symptoms of diseases that resembles 
malaria (Okeke et al., 2006). Of particular 
interest to this study is the recommendation 
for the intermittent preventive treatment of 
malaria with SP in pregnancy (IPTP-SP), for 
the control of malaria (WHO, 2013) and the 
reduction of its adverse effects, during the 
period of pregnancy (Moussiliou et al., 2013; 
Tan et al., 2014). However, it has been shown 
that in areas with a known history of wide 
spread drug resistance, IPTP-SP may not 
confer benefit during the period of pregnancy 
(Harrington et al., 2011).  
 In order to determine how relevant SP 
may be for its recommended purpose among 
pregnancies in some Nigerian women, we 
decided to survey the frequency distribution 
of SNPs in the dihydrofolate reductase (dhfr) 
and dihydropteroate synthase (dhps) genes of 
P. falciparum parasites among pregnant 
women in Makurdi. These were women who 
had started their antenatal visits, but had not 
yet been administered any dose of SP. The 
aim was to determine whether prior to the 
start of IPTP-SP beginning from the second 
trimester of pregnancy, molecular markers of 
in vivo P. falciparum resistance to SP were 
already pre-expressed among these 
pregnancies. Especially if the levels were such 
that could further compromise curative doses 
of SP that were to be subsequently 
administered, beginning from the 16th week of 
the gestation period. 
 
MATERIALS AND METHODS 
Study area 
Samples for this study were collected at 
the Bishop Murray Medical Centre, and the 
Federal Medical Centre. Both medical 
facilities are located in Makurdi, north central 
Nigeria. Ethical approval was obtained from 
each hospital.  
 
Subjects and blood sample collection 
Blood samples were collected from 
pregnant women attending antenatal clinics, 
aged 18-38 years. The mean age of subjects 
was 28 ± 11 years; each subject’s consent was 
sought and obtained after the purpose of the 
study was explained to each of them. Among 
the subjects, the inclusion criteria included 
those whose gestation period were below 16 
weeks either from known knowledge of scan 
results or last menstrual period, and had 
denied taking any antimalarial drug during the 
period of pregnancy. During blood sample 
collection, a few drops of finger prick blood 




from each participant were squeezed on a pre-
labeled piece of Whatman 3MM filter paper, 
allowed to air dry and preserved in an air tight 
container with silica gel. A further single drop 
of blood from the same subject was also 
spotted twice on an identically labeled clean 
microscopy slide for both thick and thin blood 
films preparation. The air dried thick blood 
films were stained with 10% Giemsa solution 
for 10 minutes, and screened under the 
microscope for the presence of malaria 
parasites. Slides with parasite density of ≥ 
2500 parasites/µl of blood were further 
identified to species level using thin blood 
films stained with 2.5% Giemsa stain for 45 
minutes. A total of 82 malaria positive slides 
were matched with their corresponding blood 
soaked filter papers, which were then selected 
for malaria parasite DNA extraction. Sample 
collection lasted from April 2008 to April 
2009. 
  
Parasite DNA extraction 
 Parasite DNA was extracted from 
approximately 3 mm2 piece of blood blotted 
filter paper, using standard methanol-
fixation/heat extraction procedure (Djimde et 
al., 2001). A 5 µl solution of the DNA was 
used as template for nested polymerase chain 
reaction (PCR) in a total reaction volume 
mixture of 25 µl.  
 
PCR amplification of dhfr and dhps genes 
 Parasite DNA was amplified for 
detection of SNPs in the dhfr and dhps genes 
by nested PCR using published primers 
(Duraisingh et al., 1998). The PCR was 
performed on PTC 200 Peltier thermal cycler. 
The primary reaction was 45 cycles for both 
dhfr/dhps genes with these conditions: 
primary denaturation of DNA at 94 ºC for 3 
minutes, strands separation at 94 ºC for 1 
minute, primers annealing temperature of 50 
ºC for 2 minutes, Taq polymerase DNA 
synthesis at 72 ºC for 2 minutes, and final 
primers extension at 72 ºC for 15 minutes. 
Similar conditions were applicable to the 
secondary amplification of 35 reaction cycles 
for both genes except that, the annealing 
temperature for the primers was reduced to 45 
ºC for 2 minutes, while the final primers 
extension time was also reduced to 10 minutes 
at 72 ºC. A total of 71 of 82 samples (86.59%) 
were successfully amplified.    
 
Enzyme restriction digestion of dhfr and 
dhps amplicons 
A 5 µl volume of the secondary PCR 
products from each test sample was digested 
with a recommended restriction enzyme, from 
New England Biolabs using the restriction 
fragment length polymorphisms (RFLP) 
procedure (Duraisingh et al., 1998; Kublin et 
al., 2002). Appropriate recommended 
restriction enzymes were used in order to 
detect the various SNPs at dhfr and dhps 
codons. In each case, the secondary reaction 
product of PCR, and the enzyme were 
incubated overnight at a specific temperature, 
based on standard protocols (Duraisingh et al., 
1998). Digested parasite DNA fragments were 
separated on 2 % agarose gel electrophoresis.  
 
Separation of enzyme digests on agarose gel 
electrophoresis 
 The fragments formed by enzyme 
digestion were separated on 2% agarose gel 
electrophoresis together with DNA molecular 
size markers in TAE buffer. The gels were 
stained with ethidium bromide and 
photographed under UV light for visual 
inspection of fragment sizes (Duraisingh et 
al., 1998; Kubin et al., 2002). All the 71 
amplified DNA fragments were digested and 
analysed at dhfr codons 51, 59, 108, 164 and 
dhps codons 436, 437, and 540. Direct 
counting of SNPs was performed (Hastings et 
al., 2010) and codons with mixed alleles (wild 
type/mutant) were classified as mutants. 
Haplotypes were classified based on a slight 
modification of the Molecular Module, 
WWARN (2011). The SNP on dhps 436 was 
classified as an alternative wild type (Basco 
and Ringwald, 1998; Nzila, 2000). Thus 
fragments bearing both dhps 436A and 437G 
were not classified as double mutants. 





The frequency of haplotypes was 
expressed as percentages. The total number of 
haplotypes with less than three dhfr SNPs 
which could be cleared by SP treatment i  
vivo was compared with those with at least 
three dhfr SNPs or more at the dhps that could 
potentially resist SP treatment in vivo using 
the chi-square test. The test was performed 
with SPSS version 20 IBM Inc. The level of 
significance was set as P ≤ 0.05. 
 
RESULTS 
Tables 1 and 2 each shows the 
percentage frequencies of P. falciparum dhfr 
and dhps haplotypes respectively, from the 
successfully amplified DNA fragments of the 
malaria parasites. Only 4.23% of the malaria 
parasites had wild type haplotypes at dhfr. 
Another 39.43% had only one SNP at dhfr 
108. This codon was highly mixed with wild 
type and mutant alleles. The remaining 
56.34% of the parasites had at least two SNPs 
at dhfr 51, 59, or 108 that are associated with 
pyrimethamine resistance, either in mixed or 
pure form. However, there was no haplotype 
bearing the I164L mutant in the parasite 
population. In all, 5 different haplotypes were 
identified at the dhfr. Similarly, at the dhps 
loci, 4.23% of the malaria parasites had wild 
type alleles based on dhps 436, 437, and 540. 
The remaining 95.77% had acquired at least 
one of the SNPs associated with resistance to 
sulfadoxine. The K540E mutant was also not 
seen among the 5 different haplotypes that 
were observed. Two cases of wild type and 
mutant allele mixtures were observed at the 
dhps codon 436. This was a huge contrast 
compared to the dhfr where majority of the 
parasites were mixed at codon 108. 
Haplotypes with SNPs at both dhfr 436 and 
437 were classified as single mutant (Table 2) 
since 436A was considered an alternative wild 
type.  
The combination of both dhfr and dhps 
haplotypes produced 15 different genotypes. 
However, none of these was a wild type 
(Table 3). Triple mutant dhfr haplotypes with, 
or without additional mutations at the dhps 
gene which are mostly associated with 
resistance to SP in vivo accounted for 35.23% 
of the parasites (Figure 1); either as pure or 
mixed forms. There was a significant 
difference (χ2 = 6.21, df = 1, P = 0.01) 
between the total number of parasites with 
less than triple mutant haplotypes, compared 
to the combined number of triple/quadruple 
mutant haplotypes, based on the chi-square 
test. 
 
Table 1:  Haplotypes of P. falciparum dhfr gene in Makurdi. 
 
N51I C59R S108N I164L Type n       % Frequency 
N C S I wild type 3    4.23 
N C S/N I mixed single mutant 28   39.43 
N R S/N I Mixed double mutant 15   21.13 
I R N I pure triple mutant 5    7.04 
I R S/N I mixed triple mutant 20   28.17 
 
 
Table 2: Haplotypes of P. falciparum dhps gene in Makurdi. 
 
S436A* A437G K540E Type n  % Frequency 
S A K wild type 3      4.23 
A A K alternative wild type 21    29.58 
S G K Single mutant 36     50.70 
S/A G K mixed single mutant 2       2.82 
A G K  single mutant 9    12.67 
         *= alternative wild type allele. 




Table 3: Genotypes of P. falciparum dhfr/dhps genes in Makurdi. 
 
N51I C59R S108N S436A* A437G n % Frequency 
N C S S G 3 4.23 
N R S/N A G 2 2.83 
N R S/N A A 5 7.04 
N R S/N S G 8 11.26 
N C S/N A A         11 15.49 
N C S/N A G 2 2.82 
N C S/N S A 1 1.40 
N C S/N S G 12 16.90 
N C S/N S/A G 2 2.82 
I R N A G 3 4.23 
I R N S G 2 2.82 
I R S/N A A 5 7.04 
I R S/N S G 11 15.49 
I R S/N A G 2 2.82 
I R S/N S A 2 2.82 









Just before the Federal Ministry of 
Health in Nigeria migrated from malaria 
monotherapy to the ACTs, the primary drug 
for the treatment of uncomplicated malaria 
was the antifolate antimalarial drug SP, which 
replaced chroloquine as the drug of choice for 
the treatment of the disease. This replacement 
was evidenced based as resistance to the latter 
drug had reached unacceptable levels (Oguche 
et al., 2004). Although the shift to ACTs has 
been achieved, SP monotherapy is still 
common in Nigeria both in rural and urban 
areas (Okeke et al., 2006; Omole and 
Onademuren, 2010). The use of the drug as 
malaria monotherapy, even in recent times is 
commonly promoted by patent medicine 
vendors, who employ presumptive diagnosis 




and treatment of clinical malaria among 
patients that patronize them.  This is in 
addition to its main role as drug to be 
administered for IPTP during the period of 
pregnancy, in line with current 
recommendations (WHO, 2010; WHO, 2013). 
Thus, the unquestionable relevance of SP, 
whether as a mono or a combination therapy 
against malaria in Nigeria, and its importance 
in IPTP among pregnant women, calls for 
frequent monitoring of its efficacy. This is 
needed especially in virgin areas, where such 
data are not readily available. Therefore, this 
surveillance study among pregnant women, 
who were scheduled to start IPTP-SP, became 
necessary to ascertain whether the expression 
of mutant haplotypes of P. falciparum, as 
markers of SP resistance, prior to the start of 
IPTP would be capable of rendering their 
subsequent treatment with SP ineffective, for 
malaria control in pregnancy. 
Our data suggest that approximately 
35% of the P. falciparum parasites, recovered 
from our study subjects harboured 
triple/quadruple mutant haplotypes. They 
were therefore more likely to develop 
resistance to SP during treatment. However, 
this seemingly large proportion of the 
parasites that potentially could resist treatment 
to SP was significantly less than the nearly 
65% of parasites with less than a triple SNPs 
that could be cleared by the drug in vivo 
(Kublin et al., 2002; Djimde et al., 2008; Tan 
et al., 2014). Sulfadoxine/pyrimethamine 
could still be very useful for the purpose of 
IPTP among our subjects in the study area, 
provided that at the start of IPTP-SP, the drug 
should be able to reduce in vivo, the less than 
triple mutant haplotypes along with a 
significant portion of the triple/quadruple 
mutant parasites. For instance, the 
composition of triple/quadruple mutant 
haplotypes indicated that only 7.04% was pure 
quadruple mutants. The remaining 28.17% 
was made up of 9.86% mixed triple mutant 
and 18.31% mixed quadruple mutant 
haplotypes. The presence of mixed haplotypes 
could imply two possibilities during actual 
treatment. First, mutant alleles could revert to 
wild type (Nzila et al., 2000) and may be 
cleared by the drug in vivo, thus ensuring that 
the actual parasite resistance to SP in the 
sampled population of pregnant women may 
be lower than 35.21%.  A second alternative 
could be that in the face of actual treatment, 
wild type alleles would further mutate to 
mutant alleles, with SP unable to clear the 
parasites. This would increase in vivo 
resistance to the drug beyond 35% and may 
further reduce the benefits that would have 
accrued to the subjects (Harrington et al., 
2011).  Rather than the first possibility, there 
is ample evidence to support the fact that 
because of the current level of resistance to 
the drug, SP treatment in most cases increases 
the level of mutant alleles, compared to that 
seen in pre-treatment samples (Nzila et al., 
2000; Djimde et al., 2008). Perhaps, the 
absence of quintuple mutant haplotype as a 
result of lack of dhfr 164L and dhps 540E in 
our samples could be that true resistance to SP 
among pregnant women in Makurdi may be 
lower than the value observed in our present 
study. However, no previous related data on 
SP treatment exist in our sample location, for 
proper comparison to be made. The lack of the 
dhfr 164L mutant haplotype in the present 
study is similar to the findings by Happi et al. 
(2005) in a sampled population of both pre-
treatment, and SP treated patients in South 
Western Nigeria. Given the fact that dhps 
540E haplotype was also not detected in this 
study, dhps 437G with a frequency of 66.20% 
was the only dhps allele, that in combination 
with triple mutant dhfr haplotypes could 
increase the overall parasite resistance to SP 
in vivo. The 436A SNP did occurred in our 
sample but in Africa, its overall contribution 
to SP resistance may be less important than 
the 437G and the 540E double mutant 
haplotypes (Nzila et al., 2000). The later was 
completely absent, which effectively meant 
that only quadruple mutant haplotypes at most 
were seen in our sample. In some parts of 
Africa, there are reports that even in the 
presence of very high penetration of the 
quintuple mutant haplotype; IPTP-SP was 
found to be very useful in reducing the 
adverse impact of malaria, during the period 
of pregnancy (Gutman et al., 2013; Tan et al., 
2014). On the other hand there are some data 
that support the view that SP may not confer 




benefits in IPTP, in an area of wide spread 
antimalarial drug resistance (Harrington et al., 
2011; Mossiliou et al., 2013). Our data 
although, not a direct observation in the 
course of SP treatment hints to a possible rise 
in the level of resistance markers that may 
render in vivo treatment with SP rather 
ineffective in  the course of actual treatment 
with the drug.   
Would such ineffective treatment 
completely abolish the benefits that would 
have accrued to the pregnancies assuming SP 
were to be very effective? No; SP may 
continue to be beneficial for the purpose of 
IPTP because even in a presumably worst case 
scenario where quintuple mutant haplotype 
had 100% penetration, treatment with the drug 
significantly reduced adverse effects of 
malaria on pregnancies (Gutman et al., 2013; 
Tan et al., 2014). Thus given that the 
quintuple mutant haplotype is less likely to be 
found in our study area during actual 
treatment with SP; it could be that perhaps, on 
a comparative basis, IPTP-SP may be more 
beneficial to our study population, compared 
to areas where the quintuple mutant haplotype 
already existed on a greater scale.  
Our study was narrowly confined, to 
investigating the molecular evidence that 
suggests SP resistance prior to the beginning 
of IPTP-SP, and our evidence was based on a 
rather small sample size. Accordingly, we 
encourage further surveillance involving a 
larger sample size that would include similar 
category of subjects we have studied 
presently. In addition, those receiving IPTP-SP 
should be included in the same study as well. 
This will facilitate better comparison to enable 
us elucidate the true level of SP resistance, 
and its consequences on pregnancies in our 
study area, and other similar locations.  
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